Ebert D, Albert R, May A, Stosiek I, Kaschka W
Department of Psychiatry, University of Erlangen, Germany.
Psychopharmacology (Berl). 1995 Jun;119(3):342-4. doi: 10.1007/BF02246301.
Eighteen patients with refractory depression (dysthymia with superimposed major depression) were treated with a combination of fluvoxamine and moclobemide for 6 weeks and compared with 18 patients treated with fluvoxamine only. Both groups had improved only slightly after 8 weeks of TCA treatment and 6 weeks of SSRI treatment. Two main observations can be made concerning safety and efficacy. Firstly, side effects in the SSRI-RIMA group were minimal. Secondly, the SSRI-RIMA combination treatment significantly improved depression in refractory depressed patients, with a decrease in depression of about 40%. The SSRI monotherapy group also significantly improved, though only by about 20%, indicating that positive effects of SSRI treatment may still develop even after 12 weeks of treatment. In conclusion, the study gives further support to the hypothesis that SSRI-RIMA combinations may be safe and well tolerated. This treatment may also offer some therapeutic advantages in at least some patients who have not responded to conventional pharmacological treatment.
18例难治性抑郁症（恶劣心境叠加重度抑郁）患者接受氟伏沙明与吗氯贝胺联合治疗6周，并与18例仅接受氟伏沙明治疗的患者进行比较。两组在接受8周三环类抗抑郁药（TCA）治疗和6周选择性5-羟色胺再摄取抑制剂（SSRI）治疗后改善均甚微。关于安全性和疗效有两点主要观察结果。其一，SSRI-RIMA组的副作用极小。其二，SSRI-RIMA联合治疗显著改善了难治性抑郁症患者的抑郁状况，抑郁程度降低了约40%。SSRI单药治疗组也有显著改善，不过仅约20%，这表明即使在治疗12周后，SSRI治疗的积极效果仍可能显现。总之，该研究进一步支持了SSRI-RIMA联合用药可能安全且耐受性良好的假说。这种治疗方法可能也为至少一些对传统药物治疗无反应的患者提供了一些治疗优势。
